Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Rinaldo Pellicano
 + 2588 word(s) 2588 2022-01-12 04:58:09 |
2 update references and layout
Amina Yu
 Meta information modification 2588 2022-01-26 02:00:42 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Pellicano, R. Extra-Intestinal Manifestations of Celiac Disease. Encyclopedia. Available online: https://encyclopedia.pub/entry/18758 (accessed on 03 September 2024).
Pellicano R. Extra-Intestinal Manifestations of Celiac Disease. Encyclopedia. Available at: https://encyclopedia.pub/entry/18758. Accessed September 03, 2024.
Pellicano, Rinaldo. "Extra-Intestinal Manifestations of Celiac Disease" Encyclopedia, https://encyclopedia.pub/entry/18758 (accessed September 03, 2024).
Pellicano, R. (2022, January 25). Extra-Intestinal Manifestations of Celiac Disease. In Encyclopedia. https://encyclopedia.pub/entry/18758
Pellicano, Rinaldo. "Extra-Intestinal Manifestations of Celiac Disease." Encyclopedia. Web. 25 January, 2022.
Extra-Intestinal Manifestations of Celiac Disease
Edit
This entry is adapted from the peer-reviewed paper 10.3390/jcm11010258

Celiac disease (CD) is a chronic, small-intestinal, immune-mediated enteropathy due to gluten exposition in genetically predisposed individuals. It occurs in about 1% of the population and often remains an underdiagnosed condition. This could be due to the fact that the adult population often lacks the classical signs and symptoms of CD, manifesting only atypical symptoms.

celiac disease extraintestinal diagnosis clinical presentation gluten-free diet

1. Neurological Manifestations

The relationship between CD and neurologic disorders was first described in 1966, by Cooke and Smith [1], who observed evidence of cerebellar ataxia and peripheral neuropathies in some CD patients. Nowadays, although gluten neuropathy and ataxia remain the most common [2], many other neurologic disorders have been correlated to CD, such as headache, epilepsy, and cognitive impairment [3].
Overall, it has been estimated that one-fifth of CD patients suffer from neurological manifestations [4]. A recent study by Hadjivassiliou et al. [5] observed that at the time of diagnosis, 67% of patients already have signs of neurologic dysfunction.
However, the precise pathophysiological process of neurological involvement in CD remains partially unclear. Certainly, the nervous system undergoes many gluten-mediated mechanisms, including cross-reacting antibodies, immune-complex deposition, direct toxicity and gut–microbiota–brain axis alteration [6]. In recent years, some authors have also hypothesized that neurologic disorders could be a consequence of an abnormal brain perfusion [3][7]. Using single-photon emission computed tomography, they noted the presence of cerebral hypoperfusion in CD patients, which might be related to intestinal hyperemia and/or perivascular inflammation [3].

1.1. Ataxia

Cerebellar ataxia (CA), also called gluten ataxia, is one of the first neurologic symptoms and one of the most frequent in patients with CD [1]. A recent systematic review estimated the prevalence of gluten ataxia to be 0–6% among CD patients and observed that ataxia accounts for a higher percentage of neurological manifestations in CD adults compared to children [3].
CA could be the only and first clinical manifestation of CD. It usually appears in late mean age (55 years old) and without any other associated gastrointestinal symptoms [8].
In most cases (69%), symptoms are mild and include difficulty with arm and leg control, altered movements of eyes and poor coordination. However, in one-third of patients CA leads to a progressive impairment of stability with moderate/severe gait manifestations which require walking support or even wheelchair use [9].
From a histological point of view, patients with gluten ataxia show a particular type of neurologic deficit consisting of the loss of Purkinje cells. This damage was firstly attributed to vitamins deficiencies, such as B1, B3, B6, and B12, which were well-known causes of neurological disorders [10]. However, later findings demonstrated an immune-mediated pathogenesis [10]. In fact, AGA and anti-tTG (particularly tTG6) have shown reactivity with the deep cerebellar nuclei brainstem and cortical neurons, which bring to a cross-reaction with Purkinje cells and their consequent damage [2][5][10]. So, it is not surprising that the prevalence of circulating AGAs and/or tTG6 antibodies was found to be higher in CD patients with CA rather than in those without neurological problems (73% vs. 40%) [5].
Diet seems to be effective on gluten ataxia—the higher the adherence to a strict GFD, the better are the improvements in cerebellar function and clinical manifestations [10]. These effects are probably due to the positive impact of gluten exclusion on autoimmunity mechanisms. However, ataxic symptom relief with a GFD has been proven only in adult CD patients. Hence, its usefulness is unclear among children [2].

1.2. Peripheral Neuropathy

Peripheral neuropathy is the second-most-common neurological manifestation reported in CD patients [1][2]. Its prevalence ranges from 2% to 23%, with higher rates among females and older patients [2][5][11].
The presence of peripheral neuropathy is often discovered from mild sub-clinical manifestations such as lower sensibility to pain threshold, warm or skin contact, feeling of numbness or tingling, and writing difficulty [1][12]. It is usually described as a symmetric neuropathy, so it involves both the arms and legs, and it can progressively lead to gait instability.
As a characteristic symptom does not exist, a skin or nerve biopsy is needed to confirm the diagnosis. Unlike gluten ataxia, in the case of neuropathy histological examination highlights the loss of myelinated fibers [12].
The effect of a GFD on peripheral neuropathy is still unclear. Some studies suggest that a GFD could improve nerve function and symptoms. However, diet adherence seems not to prevent neuropathy development and the severity of the disease is not associated with GFD duration [13].

1.3. Headache, Epilepsy, and Cognitive Impairment

Other neurological manifestations correlated to CD are headache, epilepsy, and cognitive impairment [3].
In the early 2000s, Cicarelli et al. observed a higher prevalence of headache among CD patients and used, for the first time, the term “gluten encephalopathy” [14]. This condition is characterized by episodic headache attacks, which are similar to migraine and affect about 26% of celiac population [15].
From a histological point of view, CD patients with headache show some white manner alterations at magnetic resonance neurography (MRN). These lesions seem to be correlated not so much to demyelination as to a vascular inflammation process [12].
Adherence to a GFD is effective for symptom improvement and leads to total resolution of headaches in up to 75% of patients. The precise mechanism of this effect remains unclear, but it is probably due to inflammation reduction. Nevertheless, a GFD is not able to resolve white matter abnormalities [15][16].
Instead, Pfaender et al. collected a series of cases in which children with biopsy-confirmed CD had epilepsy and bilateral occipital calcifications [17]. This association was also described by other authors [18][19], who suggested that HLA genotypes predisposing to CD could be the same as those predisposing to bilateral occipital calcifications and epilepsy [17].
The risk of epilepsy in CD population is increased of 1.4 times, with a prevalence of 1–6%. However, neither the etiopathogenesis nor the correlation between CD and epileptic crisis are completely understood [20]. Some researchers have associated the presence of cerebral calcifications to a gluten-toxicity process [21][22].
Manifestations of CD crisis are very similar to those of epileptic syndrome, including blurred vision and colored dots’ view, and they are usually well controlled by antiepileptic medications [12].
The effect of a GFD is evident in most patients, in whom it determines better seizure control, decreased drug use, and even complete resolution. Moreover, a GFD seems to arrest cerebral calcification development [18][21].
CD can also cause cognitive function damage. The presence of cognitive impairment in celiac patients was first reported by Kinney et al. [23]. Since then, many studies have confirmed the correlation between CD and cognitive impairment, but its real prevalence remains difficult to define. In fact, symptoms are non-specific and variable, in both severity and duration. Usually, they are mild and transient, and include difficulties in concentration, inattention, struggling to find words, and episodic memory deficits. The condition of slight cognitive alteration, that is known as “brain fog”, is the most common symptom among CD patients [24]. However, in some cases, cognitive impairment gets worse and may lead to confusion, disorientation, and even dementia [24].
Several mechanisms have been proposed to explain the gluten-induced deleterious process. Nowadays, two hypotheses are the most accredited. The first attributes cognitive damage to systemic inflammation caused by CD, which also favors cerebral inflammation and consequent reduction in neuronal transmission speed. The second blames gluten for indirectly reducing brain serotonin levels [24][25].
From a histological point of view, patients with cognitive impairment do not show particular radiological lesions; at most, diffuse cerebral atrophy can be observed. For this reason, diagnosis can be performed only through neuropsychological tests [24].
A GFD is effective for brain fog and other mild alterations, which often completely disappear. However, its effect on more severe forms remains controversial [26].

2. Neuropsychiatric Manifestations

The relationship between CD and psychiatric disorders is known, but it is not yet fully recognized and understood. Depression, anxiety, attention deficit/hyperactivity disorder (ADHD), and autism are the most frequent neuropsychiatric manifestations in celiac patients [27].
The precise pathophysiological mechanism of gluten-induced psychiatric involvement is unclear. However, both biological and social factors might be involved. Biological explanations include inflammation processes, autoimmunity activity, microbiota composition, and the gut–brain axis relationship, but evidence in this regard is scarce especially due to small sample sizes of the studies [27]. Instead, social implications are easier to guess. They include all the possible negative consequences of GFD introduction, such as social isolation or avoiding going out because of difficult meal management and contamination risk [27][28].

2.1. Depression

Smith et al. observed that depressive disturbance was more common and more severe among adult CD subjects [29]. According to a recent systematic review, the risk of depression development is higher in this cohort, with a mean prevalence of 3.5% [27].
The increased risk has been explained by various biological hypotheses, such as low levels of serotonin due to tryptophan malabsorption, concomitant presence of hypothyroidism, and increased hypothalamic–pituitary–adrenal axis activity [27][28]. On the other hand, adherence to a strict dietary regimen can induce patients to avoid social situations involving food, and to have higher levels of stress because of meal difficulties and worries. All these psycho–social conditions certainly contribute to depression onset and progression [28].
As diet stress is one of the possible contributing causes of depressive manifestations, the role of a GFD is controversial. Some studies observed improvement with GFD adherence, especially after long-term administration [30], while others even reported the worsening of depressive symptoms [27][31].

2.2. Anxiety, ADHD, and Autism

Anxiety states are more common among new-diagnosed CD patients. In fact, the introduction of a GFD leads the subject to make many changes in eating habits and lifestyle, which can result in agitation and feelings of stress [28]. However, this condition usually ameliorates after 1 year of GFD [31].
ADHD affects about 1.4% of CD patients, whose risk is higher compared to the general population [28]. A preliminary study by Niederhofer et al. found an “overexpression” of ADHD symptoms in a group of celiac subjects, which improved in the majority of them (74%) after 6 months of a GFD [32].
A significant increase in risk development has also been observed for autistic spectrum disorders, in which an appropriate compliance to a GFD seems to improve behavioral symptoms [28].
Although the correlation of anxiety, ADHD, autism, and CD is often described, precise etiological mechanisms and specific biological explanations of GFD effectiveness remain unclear and need further investigation.

2.3. Other Psychiatric Disorders

Evidence concerning correlation between CD and other psychiatric disorders is very limited and mainly published as case reports.
Some researchers recently hypothesized that CD patients are at higher risk of having eating disorders. However, only a few studies have investigated the impact of a GFD on them [27].
Many surveys have evidenced symptom improvement in schizophrenic subjects after the introduction of a GFD. This has stimulated scientists to investigate the possible association between CD and schizophrenia, also through research on genetic similarities [33][34]. However, recent studies challenged this theory and showed no significant correlations [27].
Likewise, no significant differences in prevalence and risk have been observed for bipolar disorder [27].

3. Liver Manifestations

It is not rare that CD is included in the history of illness signs of hepatic injury.
Liver damage can be due to a dysmetabolic condition, such as non-alcoholic fatty liver disease [35], or to a concomitant autoimmune disease, such as autoimmune hepatitis [36]. However, recent studies showed elevated aminotransferase levels in celiac patients without known causes of liver disease [37][38]. This condition has been called “gluten-induced hepatitis”, with a prevalence of 4–9% reported by recent studies [39].
Usually, hepatic injury is mild and easily reversible, leading to liver failure on rare occasions. Behind the physio-pathological mechanism of the hepatotoxicity, there is the alteration of gut permeability, which leads to an increased exposure to hepatotoxins in the portal circulation [37]. Moreover, a few studies have reported histological evidence of tTG2 autoantibody deposits in liver biopsies from CD patients, suggesting their direct involvement in hepatocellular damage [4].
So, the search for CD should be performed in subjects who present no symptoms of chronic liver disease nor other reasons for high transaminase levels [37]. The severity of the hypertransaminasemia has been associated with the presence of malabsorption, high titer of celiac autoantibodies and severe duodenal lesions [40]. When a liver biopsy is performed, generally in patients who show persistently high liver enzyme levels, a minimal grade steatosis or a reactive nonspecific hepatitis can be observed [37].
In celiac patients, liver condition is generally benign and reversible—GFD usually leads to injury resolution and transaminases normalization within 6–12 months [39].
Since it may often occur as an isolated hypertransaminasemia in the absence of other gastrointestinal symptoms, it must be included in hepatitis differential diagnosis [38]. Only where CD is unrecognized or untreated and the liver involvement is subclinical, is progression of the hepatic involvement to be feared. Surprisingly, as a few studies have demonstrated, GFD allows a clinical improvement even in these more severe conditions [38][41].
Therefore, CD has to be carefully investigated in all patients with hepatitis of unknown etiology, since early detection and treatment can prevent the progression to severe liver disease [37].

4. Reproductive Manifestations

It is known that CD can cause inflammation and malabsorption. Both these conditions might be responsible, or at least partially contribute, to infertility [42]. However, some researchers have also proposed the possible role of autoimmunity, suggesting that anti-tTG antibodies may be responsible for the inhibition of endometrial angiogenesis [43]. Whatever the cause, GFD seems to be effective. In fact, celiac women undergoing a GFD have a fertility which is comparable to healthy ones [44][45], whereas women who do not follow a GFD can manifest several conditions such as late menarche, secondary amenorrhea, early menopause, miscarriages, preterm pregnancy, and low birth weight of the newborn [45][46][47][48]. Specifically, the risk of recurrent miscarriages is eight to nine times higher in celiac women who do not follow a GFD than in the general population [49]. As observed by Fortunato et al. [50], prevalence of reproductive disorders is higher in patients with CD compared to the general population, suggesting how it may be useful to test for CD in women presenting changes during pregnancy or infertility [50].
Thus, CD can be considered as a risk factor for infertility. The favorable response to a GFD can justify the serological screening for CD among women with infertility of unknown origin [48][51]
Nevertheless, not all the studies agree with this theory. In a recent meta-analysis, the authors reported that using a more stringent definition of CD (confirmed by biopsy requiring a Marsh type III villous atrophy), the prevalence of this condition in women with infertility should be similar to that observed in the general population [51]. This stands in contrast to the meta-analyses by Castano et al. and Singh et al. who instead found a higher prevalence of infertility in patients with CD [52][53]. One of the reasons why this difference can be observed may be found in the definition of CD—some studies have considered Marsh type I as sufficient for the diagnosis of disease while others have not even used Marsh’s criteria for diagnosis. In the meta-analysis by Glimberg et al., CD diagnosis had to be verified by a biopsy that confirmed a Marsh type III and excluded couples in which the underlying problem was male infertility. In a second analysis, studies were evaluated in which, for the definition of CD, the presence of IgA tTG was sufficient [54]. However, the authors highlight how the lack of fertile women used as control can be a limitation as well as the low number of participants in the majority of the studies [54]. Further cohort studies are needed to better understand the correlation between CD and infertility.
Focusing on the male population, sperm abnormalities both in terms of morphology and motility can be observed in CD patients [55][56]. From a strictly biochemical point of view, some studies reported a condition of androgen resistance, which means high testosterone levels and high LH values [55][56]. However, androgen resistance seems to respond to a GFD. In fact, a study conducted on 41 CD males with androgen resistance showed that a GFD determined the normalization of biochemical alterations [56].

References

  1. Cooke, W.T.; Smith, W.T. Neurological disorders associated with adult coeliac disease. Brain 1966, 89, 683–722.
  2. Mearns, E.S.; Taylor, A.; Thomas Craig, K.J.; Puglielli, S.; Cichewicz, A.B.; Leffler, D.A.; Sanders, D.S.; Lebwohl, B.; Hadjivassiliou, M. Neurological manifestations of neuropathy and ataxia in celiac disease: A systematic review. Nutrients 2019, 11, 380.
  3. Pennisi, M.; Bramanti, A.; Cantone, M.; Pennisi, G.; Bella, R.; Lanza, G. Neurophysiology of the “celiac brain”: Disentangling gut-brain connections. Front. Neurosci. 2017, 11, 498.
  4. Laurikka, P.; Nurminen, S.; Kivelä, L.; Kurppa, K. Extraintestinal Manifestations of Celiac Disease: Early Detection for Better Long-Term Outcomes. Nutrients 2018, 10, 1015.
  5. Hadjivassiliou, M.; Croall, I.D.; Zis, P.; Sarrigiannis, P.G.; Sanders, D.S.; Aeschlimann, P.; Grünewald, R.A.; Armitage, P.A.; Connolly, D.; Aeschlimann, D.; et al. Neurologic deficits in patients with newly diagnosed celiac disease are frequent and linked with autoimmunity to transglutaminase 6. Clin. Gastroenterol. Hepatol. 2019, 17, 2678–2686.
  6. Ford, R.P. The gluten syndrome: A neurological disease. Med. Hypotheses 2009, 73, 438–440.
  7. Abenavoli, L. Brain hypoperfusion and neurological symptoms in celiac disease. Mov. Disord. 2010, 25, 799–800.
  8. Hadjivassiliou, M.; Gibson, A.; Davies-Jones, G.A.; Lobo, A.J.; Stephenson, T.J.; Milford-Ward, A. Does Cryptic Gluten Sensitivity play a part in Neurological Illness? Lancet 1996, 346, 369–371.
  9. Hadjivassiliou, M.; Rao, D.G.; Grinewald, R.A.; Aeschlimann, D.P.; Sarrigiannis, P.G.; Hoggard, N.; Aeschlimann, P.; Mooney, P.D.; Sanders, D.S. Neurological Dysfunction in Coeliac Disease and Non-Coeliac Gluten Sensitivity. Am. J. Gastroenterol. 2016, 111, 561–567.
  10. Rouvroye, M.D.; Zis, P.; Van Dam, A.M.; Rozemuller, A.J.M.; Bouma, G.; Hadjivassiliou, M. The Neuropathology of Gluten-Related Neurological Disorders: A Systematic Review. Nutrients 2020, 12, 822.
  11. Luostarinen, L.; Hinamen, S.L.; Luostarinen, M.; Collin, P.; Pirttilä, T. Neuromuscular and sensory disturbances in patients with well-treated coeliac disease. J. Neurol. Neurosurg. Psychiatry 2003, 74, 490–494.
  12. Casella, G.; Bordo, B.M.; Schalling, R.; Villanacci, V.; Salemme, M.; Di Bella, C.; Baldini, V.; Bassotti, G. Neurological disorders and celiac disease. Minerva Gastroenterol. Dietol. 2016, 62, 197–206.
  13. Shen, T.C.; Lebwohl, B.; Verma, H.; Kumta, N.; Tennyson, C.; Lewis, S.; Scherl, E.; Swaminath, A.; Capiak, K.M.; DiGiacomo, D.; et al. Peripheral neuropathic symptoms in celiac disease and inflammatory bowel disease. J. Clin. Neuromuscul. Dis. 2012, 13, 137–145.
  14. Cicarelli, G.; Della Rocca, G.; Amboni, M.; Ciacci, C.; Mazzacca, G.; Filla, A.; Barone, P. Clinical and neurological abnormalities in adult celiac disease. Neurol. Sci. 2003, 24, 311–317.
  15. Zis, P.; Julian, T.; Hadjivassiliou, M. Headache associated with coeliac disease: A systematic review and meta-analysis. Nutrients 2018, 10, 1445.
  16. Ameghino, L.; Farez, M.F.; Wilken, M.; Goicochea, M.T. Headache in Patients with Celiac Disease and Its Response to the Gluten-Free Diet. J. Oral Facial Pain Headache 2019, 33, 294–300.
  17. Pfaender, M.; D’Souza, W.J.; Trost, N.; Litewka, L.; Paine, M.; Cook, M. Visual disturbances representing occipital lobe epilepsy in patients with cerebral calcifications and coeliac disease: A case series. J. Neurol. Neurosurg. Psychiatry 2004, 75, 1623–1625.
  18. Gobbi, G.; Bouquet, F.; Greco, L.; Lambertini, A.; Tassinari, C.A.; Ventura, A.; Tassinari, C.A. Coeliac disease, epilepsy, and cerebral calcifications. The Italian Working Group on Coeliac Disease and Epilepsy. Lancet 1992, 340, 439–443.
  19. Magaudda, A.; Dalla Bernardina, B.; De Marco, P.; Sfaello, Z.; Longo, M.; Colamaria, V.; Daniele, O.; Tortorella, G.; Tata, M.A.; Perri, R. Bilateral occipital calcification, epilepsy and coeliac disease: Clinical and neuroimaging features of a new syndrome. J. Neurol. Neurosurg. Psychiatry 1993, 56, 885–889.
  20. Ribaldone, D.G.; Astegiano, M.; Fagoonee, S.; Rizzetto, M.; Pellicano, R. Epilepsy and celiac disease: Review of literature. Panminerva Med. 2011, 53, 213–216.
  21. Lea, M.E.; Harbord, M.; Sage, M.R. Bilateral occipital calcification associated with celiac disease, folate deficiency, and epilepsy. Am. J. Neuroradiol. 1995, 16, 1498–1500.
  22. Ludvigsson, J.F.; Zingone, F.; Tomson, T.; Ekbom, A.; Ciacci, C. Increased risk of epilepsy in biopsy-verified celiac disease: A population-based cohort study. Neurology 2012, 78, 1401–1407.
  23. Kinney, H.C.; Burger, P.C.; Hurwitz, B.J.; Hijmans, J.C.; Grant, J.P. Degeneration of the central nervous system associated with celiac disease. J. Neurol. Sci. 1982, 53, 9–22.
  24. Makhlouf, S.; Messelmani, M.; Zaouali, J.; Mrissa, R. Cognitive impairment in celiac disease and non-celiac gluten sensitivity: Review of literature on the main cognitive impairments, the imaging and the effect of gluten free diet. Acta Neurol. Belg. 2018, 118, 21–27.
  25. Choi, S.; Di Silvio, B.; Fernstrom, M.H.; Fernstrom, J.D. Meal ingestion, amino acids and brain neurotransmitters: Effects of dietary protein source on serotonin and catecholamine synthesis rates. Physiol. Behav. 2009, 98, 156–162.
  26. Hu, W.T.; Murray, J.A.; Greenaway, M.C.; Parisi, J.E.; Josephs, K.A. Cognitive impairment and celiac disease. Arch. Neurol. 2006, 63, 1440–1446.
  27. Clappison, E.; Hadjivassiliou, M.; Zis, P. Psychiatric manifestations of coeliac disease, a systematic review and meta-analysis. Nutrients 2020, 12, 142.
  28. Campagna, G.; Pesce, M.; Tatangelo, R.; Rizzuto, A.; La Fratta, I.; Grilli, A. The progression of coeliac disease: Its neurological and psychiatric implications. Nutr. Res. Rev. 2017, 30, 25–35.
  29. Smith, D.F.; Gerdes, L.U. Meta-analysis on anxiety and depression in adult celiac disease. Acta Psychiatr. Scand. 2012, 125, 189–193.
  30. Van Hees, N.J.; Van der Does, W.; Giltay, E.J. Coeliac disease, diet adherence and depressive symptoms. J. Psychosom. Res. 2013, 74, 155–160.
  31. Addolorato, G. Anxiety but not depression decreases in coeliac patients after one-year gluten-free diet: A longitudinal study. Scand. J. Gastroenterol. 2001, 36, 502–506.
  32. Niederhofer, H.; Pittschieler, K. A preliminary investigation of ADHD symptoms in persons with celiac disease. J. Atten. Disord. 2006, 10, 200–204.
  33. Li, T.; Underhill, J.; Liu, X.H.; Sham, P.C.; Donaldson, P.; Murray, R.M.; Wright, P.; Collier, D.A. Transmission disequilibrium analysis of HLA class II DRB1, DQA1, DQB1 and DPB1 polymorphisms in schizophrenia using family trios from a Han Chinese population. Schizophr. Res. 2001, 49, 73–78.
  34. Pellicano, R.; Durazzo, M. Schizophrenia and celiac disease: Which is the role of the gluten-free diet? Eur. J. Gastroenterol. Hepatol. 2018, 30, 806–807.
  35. Valvano, M.; Longo, S.; Stefanelli, G.; Frieri, G.; Viscido, A.; Latella, G. Celiac disease, gluten-free diet, and metabolic and liver disorders. Nutrients 2020, 12, 940.
  36. Haggård, L.; Glimberg, I.; Lebwohl, B.; Sharma, R.; Verna, E.C.; Green, P.H.; Ludvigsson, J.F. High prevalence of celiac disease in autoimmune hepatitis: Systematic review and meta-analysis. Liver Int. 2021, 41, 2693–2702.
  37. Kaukinen, K.; Halme, L.; Collin, P.; Färkkilä, M.; Mäki, M.; Vehmanen, P.; Partanen, J.; Höckerstedt, K. Celiac disease in patients with severe liver disease: Gluten-free diet may reverse hepatic failure. Gastroenterology 2002, 122, 881–888.
  38. Zali, M.R.; Nejad, M.R.; Rostami, K.; Moayed, S. Liver complications in celiac disease. Hepat. Mon. 2011, 11, 333–341.
  39. Sainsbury, A.; Sanders, D.S.; Ford, A.C. Meta-analysis: Coeliac disease and hypertransaminasaemia. Aliment. Pharmacol. Ther. 2011, 34, 33–40.
  40. Nardecchia, S.; Auricchio, R.; Discepolo, V.; Troncone, R. Extra-Intestinal Manifestations of Coeliac Disease in Children: Clinical Features and Mechanisms. Front. Pediatr. 2019, 7, 56.
  41. Al-Hussaini, A.; Basheer, A.; Czaja, A.J. Liver failure unmasks celiac disease in a child. Ann. Hepatol. 2013, 12, 501–505.
  42. Ludvigsson, J.F.; Bai, J.C.; Biagi, F.; Card, T.R.; Ciacci, C.; Ciclitira, P.J.; Green, P.H.; Hadjivassiliou, M.; Holdoway, A.; Van Heel, D.A.; et al. Diagnosis and management of adult coeliac disease: Guidelines from the British Society of Gastroenterology. Gut 2014, 63, 1210–1228.
  43. Tersigni, C.; Castellani, R.; de Waure, C.; Fattorossi, A.; De Spirito, M.; Gasbarrini, A.; Scambia, G.; Di Simone, N. Celiac disease and reproductive disorders: Meta-analysis of epidemiologic associations and potential pathogenic mechanisms. Hum. Reprod. Update 2014, 20, 582–593.
  44. Tata, L.J.; Card, T.R.; Logan, R.F.A.; Hubbard, R.B.; Smith, C.J.P.; West, J. Fertility and pregnancy-related events in women with celiac disease: A population-based cohort study. Gastroenterology 2005, 128, 849–855.
  45. Moleski, S.M.; Lindenmeyer, C.C.; Veloski, J.J.; Miller, R.S.; Miller, C.L.; Kastenberg, D.; DiMarino, A.J. Increased rates of pregnancy complications in women with celiac disease. Ann. Gastroenterol. Q. Publ. Hell. Soc. Gastroenterol. 2015, 28, 236–240.
  46. Rujner, J. Age at menarche in girls with celiac disease. Ginekol. Pol. 1999, 70, 359–362.
  47. Ferguson, R.; Holmes, G.K.; Cooke, W.T. Coeliac disease, fertility, and pregnancy. Scand. J. Gastroenterol. 1982, 17, 65–68.
  48. Collin, P.; Vilska, S.; Heinonen, P.K.; Hällström, O.; Pikkarainen, P. Infertility and coeliac disease. Gut 1996, 39, 382–384.
  49. Vitale, J. Recurrent miscarriage. N. Engl. J. Med. 2011, 364, 783–784.
  50. Fortunato, F.; Martinelli, D.; Prato, R.; Pedalino, B. Results from Ad Hoc and Routinely Collected Data among Celiac Women with Infertility or Pregnancy Related Disorders: Italy, 2001–2011. Sci. World J. 2014, 2014, e614269.
  51. Ghadir, M.; Iranikhah, A.; Jandaghi, M.; Joukar, F.; Sedigh-Rahimabadi, M.; Mansour-Ghanaei, F. Unexplained infertility as primary presentation of celiac disease, a case report and literature review. Iran. J. Reprod. Med. 2011, 9, 135–140.
  52. Castaño, M.; Gómez-Gordo, R.; Cuevas, D.; Núñez, C. Systematic Review and Meta-Analysis of Prevalence of Coeliac Disease in Women with Infertility. Nutrients 2019, 11, 1950.
  53. Singh, P.; Arora, S.; Lal, S.; Strand, T.A.; Makharia, G.K. Celiac Disease in Women With Infertility: A Meta-Analysis. J. Clin. Gastroenterol. 2016, 50, 33–39.
  54. Glimberg, I.; Haggård, L.; Lebwohl, B.; Green, P.H.R.; Ludvigsson, J.F. The prevalence of celiac disease in women with infertility—A systematic review with meta-analysis. Reprod. Med. Biol. 2021, 20, 224–233.
  55. Sher, K.S.; Jayanthi, V.; Probert, C.S.J.; Stewart, C.R.; Mayberry, J.F. Infertility, Obstetric and Gynaecological Problems in Coeliac Sprue. Dig. Dis. 1994, 12, 186–190.
  56. Farthing, M.J.; Rees, L.H.; Edwards, C.R.; Dawson, A.M. Male gonadal function in coeliac disease: 2. Sex hormones. Gut 1983, 24, 127–135.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Gastroenterology & Hepatology
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Rinaldo Pellicano
View Times: 504
Revisions: 2 times (View History)
Update Date: 26 Jan 2022
Table of Contents
    1000/1000
    Hot Most Recent
    ScholarVision Creations
    Feedback